Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PharmAla-1
- Development stage
- Unknown
- Lead developer
- PharmAla Biotech
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**PharmAla-1** is a novel chemical entity (NCE) in the MDXX class of molecules, developed by PharmAla Biotech as the first output of their computational drug development pipeline. It is a patented MDMA analog designed to improve safety properties over the base MDMA molecule for potential use in treating neurological and psychiatric disorders. Preclinical research is ongoing, with proof-of-concept studies initiated, and it has received US Patent Prosecution Highway acceptance and first office action for PCT filing. PharmAla-1 is not classified as a controlled substance worldwide.[7][16][18][22]
Beyond the preview
Go deeper on PharmAla-1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PharmAla-1.